Recursion Pharmaceuticals, Inc.
RXRX
$6.35
$0.416.90%
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 58.84M | 65.18M | 49.64M | 46.24M | 44.58M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 58.84M | 65.18M | 49.64M | 46.24M | 44.58M |
| Cost of Revenue | 359.66M | 327.90M | 322.10M | 303.42M | 283.81M |
| Gross Profit | -300.82M | -262.71M | -272.47M | -257.18M | -239.24M |
| SG&A Expenses | 178.18M | 132.54M | 123.98M | 120.44M | 110.84M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 537.84M | 460.43M | 446.08M | 423.85M | 394.65M |
| Operating Income | -479.01M | -395.25M | -396.44M | -377.62M | -350.08M |
| Income Before Tax | -464.79M | -382.95M | -380.29M | -358.95M | -332.13M |
| Income Tax Expenses | -1.13M | -5.20M | -5.36M | -4.84M | -4.06M |
| Earnings from Continuing Operations | -463.66 | -377.75 | -374.93 | -354.11 | -328.07 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -463.66M | -377.75M | -374.93M | -354.11M | -328.07M |
| EBIT | -479.01M | -395.25M | -396.44M | -377.62M | -350.08M |
| EBITDA | -442.51M | -364.15M | -364.97M | -349.56M | -325.68M |
| EPS Basic | -1.66 | -1.55 | -1.64 | -1.62 | -1.57 |
| Normalized Basic EPS | -1.04 | -0.98 | -1.04 | -1.03 | -0.99 |
| EPS Diluted | -1.66 | -1.55 | -1.64 | -1.62 | -1.57 |
| Normalized Diluted EPS | -1.04 | -0.98 | -1.04 | -1.03 | -0.99 |
| Average Basic Shares Outstanding | 1.10B | 983.96M | 915.70M | 874.92M | 830.52M |
| Average Diluted Shares Outstanding | 1.10B | 983.96M | 915.70M | 874.92M | 830.52M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
